| Monique Jacqueline Brink, APRN-CNP | |
|
2510 E Independence St, Shawnee, OK 74804-1839 | |
| (800) 942-2904 | |
| Not Available |
| Full Name | Monique Jacqueline Brink |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 13 Years |
| Location | 2510 E Independence St, Shawnee, Oklahoma |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356608103 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pawhuska Hospital, Inc | Pawhuska, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pawhuska Hospital Inc | 7012906548 | 10 |
News Archive
In an important step toward developing an effective malaria vaccine, the Bill & Melinda Gates Foundation has announced a $107.6 million grant to the PATH Malaria Vaccine Initiative (MVI) to extend the public-private partnership between MVI and GlaxoSmithKline Biologicals (GSK Bio) to develop GSK Bio's malaria vaccine for children in Africa.
Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.
The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 4 days ago
| Entity Name | Pawhuska Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174521991 PECOS PAC ID: 7012906548 Enrollment ID: O20040510001389 |
News Archive
In an important step toward developing an effective malaria vaccine, the Bill & Melinda Gates Foundation has announced a $107.6 million grant to the PATH Malaria Vaccine Initiative (MVI) to extend the public-private partnership between MVI and GlaxoSmithKline Biologicals (GSK Bio) to develop GSK Bio's malaria vaccine for children in Africa.
Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.
The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 4 days ago
| Entity Name | Carnegie Tri-county Municipal Hospital Management Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275657017 PECOS PAC ID: 6800835935 Enrollment ID: O20050429000480 |
News Archive
In an important step toward developing an effective malaria vaccine, the Bill & Melinda Gates Foundation has announced a $107.6 million grant to the PATH Malaria Vaccine Initiative (MVI) to extend the public-private partnership between MVI and GlaxoSmithKline Biologicals (GSK Bio) to develop GSK Bio's malaria vaccine for children in Africa.
Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.
The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 4 days ago
| Entity Name | Deaconess Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427017862 PECOS PAC ID: 0840232070 Enrollment ID: O20050526000824 |
News Archive
In an important step toward developing an effective malaria vaccine, the Bill & Melinda Gates Foundation has announced a $107.6 million grant to the PATH Malaria Vaccine Initiative (MVI) to extend the public-private partnership between MVI and GlaxoSmithKline Biologicals (GSK Bio) to develop GSK Bio's malaria vaccine for children in Africa.
Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.
The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 4 days ago
| Entity Name | Carnegie Tri-county Municipal Hospital Management Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1043323447 PECOS PAC ID: 6800835935 Enrollment ID: O20061104000625 |
News Archive
In an important step toward developing an effective malaria vaccine, the Bill & Melinda Gates Foundation has announced a $107.6 million grant to the PATH Malaria Vaccine Initiative (MVI) to extend the public-private partnership between MVI and GlaxoSmithKline Biologicals (GSK Bio) to develop GSK Bio's malaria vaccine for children in Africa.
Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.
The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 4 days ago
| Entity Name | Minuteclinic Diagnostic Of Oklahoma Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285765727 PECOS PAC ID: 9739268897 Enrollment ID: O20080501000151 |
News Archive
In an important step toward developing an effective malaria vaccine, the Bill & Melinda Gates Foundation has announced a $107.6 million grant to the PATH Malaria Vaccine Initiative (MVI) to extend the public-private partnership between MVI and GlaxoSmithKline Biologicals (GSK Bio) to develop GSK Bio's malaria vaccine for children in Africa.
Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.
The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 4 days ago
| Entity Name | Emergency Services Of Oklahoma Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215249891 PECOS PAC ID: 8123209012 Enrollment ID: O20110225000085 |
News Archive
In an important step toward developing an effective malaria vaccine, the Bill & Melinda Gates Foundation has announced a $107.6 million grant to the PATH Malaria Vaccine Initiative (MVI) to extend the public-private partnership between MVI and GlaxoSmithKline Biologicals (GSK Bio) to develop GSK Bio's malaria vaccine for children in Africa.
Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.
The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 4 days ago
| Entity Name | True North Health Navigation Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740622133 PECOS PAC ID: 5294960696 Enrollment ID: O20180220002909 |
News Archive
In an important step toward developing an effective malaria vaccine, the Bill & Melinda Gates Foundation has announced a $107.6 million grant to the PATH Malaria Vaccine Initiative (MVI) to extend the public-private partnership between MVI and GlaxoSmithKline Biologicals (GSK Bio) to develop GSK Bio's malaria vaccine for children in Africa.
Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.
The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Monique Jacqueline Brink, APRN-CNP 3545 Nw 58th St, Ste 450, Oklahoma City, OK 73112-4726 Ph: (405) 951-4370 | Monique Jacqueline Brink, APRN-CNP 2510 E Independence St, Shawnee, OK 74804-1839 Ph: (800) 942-2904 |
News Archive
In an important step toward developing an effective malaria vaccine, the Bill & Melinda Gates Foundation has announced a $107.6 million grant to the PATH Malaria Vaccine Initiative (MVI) to extend the public-private partnership between MVI and GlaxoSmithKline Biologicals (GSK Bio) to develop GSK Bio's malaria vaccine for children in Africa.
Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.
The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.
Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.
› Verified 4 days ago
Dustin Wade, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2508 N Harrison St, Shawnee, OK 74804 Phone: 405-585-2030 | |
Mrs. Sabrina R Lafrance, CNP-FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 30 Redbud Ln, Shawnee, OK 74801 Phone: 509-554-9250 | |
Susan George, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2029 Gordon Cooper Dr, Shawnee, OK 74801 Phone: 405-878-5850 | |
Cindy Cheatwood, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2508 N Harrison St, Shawnee, OK 74804 Phone: 405-585-2030 Fax: 405-585-2859 | |
Bonnie Nadaene Grude, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 5903 Gabriel, Shawnee, OK 74804 Phone: 918-470-0324 | |
Ms. Janet Sue Pasquali Bowers, APRN, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3306 N Kickapoo Ave, Suite 150 & 154, Shawnee, OK 74804 Phone: 405-628-6535 Fax: 405-628-6532 | |
Christopher Keith Carpenter, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3214 Kethley Rd, Shawnee, OK 74804 Phone: 405-273-5801 Fax: 405-878-3814 |